The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials
The IRA's passage was associated with reductions in industry-sponsored, but not government-funded, post-approval trials, with larger reductions for small molecule drugs. These findings provide early evidence supporting concerns around IRA-related reductions in incentives for post-approval clinical development.
Authors
- Jonathan D. Campbell (ORCID: https://orcid.org/0000-0001-6539-1258)
- Julie A. Patterson (ORCID: https://orcid.org/0000-0001-5629-0842)
- Hanke Zheng (ORCID: https://orcid.org/0000-0002-4992-121X)
Institutions
- National Health Council (US)
Publication Details
- Journal
- Therapeutic Innovation & Regulatory Science
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1007/s43441-025-00774-2
- Citations
- 5
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 15.66